Michael R Clark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5047754/publications.pdf

Version: 2024-02-01

69 2,754 29 52
papers citations h-index g-index

73 73 73 2333
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Monoclonal-Antibody Therapy in Systemic Vasculitis. New England Journal of Medicine, 1990, 323, 250-254.	27.0	246
2	Antibody humanization: a case of the â€~Emperor's new clothes'?. Trends in Immunology, 2000, 21, 397	'-40'25	246
3	The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. European Journal of Immunology, 1993, 23, 403-411.	2.9	213
4	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology, 2007, 133, 312-339.	1.3	197
5	Recombinant human IgG molecules lacking $Fc\hat{l}^3$ receptor I binding and monocyte triggering activities. European Journal of Immunology, 1999, 29, 2613-2624.	2.9	173
6	Structural motifs involved in human IgG antibody effector functions. European Journal of Immunology, 1993, 23, 1098-1104.	2.9	139
7	In Vivo Detection of Vascular Adhesion Protein-1 in Experimental Inflammation. American Journal of Pathology, 2000, 157, 463-471.	3.8	101
8	IgG Effector Mechanisms. Chemical Immunology and Allergy, 1996, 65, 88-110.	1.7	80
9	Evaluation of New Treatments in Radiation Oncology. JAMA - Journal of the American Medical Association, 2005, 293, 970.	7.4	78
10	Differential binding to human FcγRlla and FcγRllb receptors by human IgG wildtype and mutant antibodies. Molecular Immunology, 2003, 40, 585-593.	2.2	68
11	Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies. Stem Cells and Development, 1995, 4, 433-437.	1.0	63
12	A humanized monovalent CD3 antibody which can activate homologous complement. European Journal of Immunology, 1991, 21, 2717-2725.	2.9	48
13	The INNs and outs of antibody nonproprietary names. MAbs, 2016, 8, 1-9.	5.2	48
14	The use of mouse/human chimaeric antibodies to investigate the roles of different antibody isotypes, including IgA2, in the killing of Schistosoma mansoni schistosomula by eosinophils. Parasite Immunology, 1993, 15, 181-185.	1.5	47
15	Advantages of rat monoclonal antibodies. Trends in Immunology, 1983, 4, 100-101.	7.5	44
16	A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. Journal of Immunological Methods, 1990, 127, 19-24.	1.4	43
17	CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunology, Immunotherapy, 1995, 40, 390-396.	4.2	43
18	The improved lytic function andin vivo efficacy of monovalent monoclonal CD3 antibodies. European Journal of Immunology, 1989, 19, 381-388.	2.9	42

#	Article	IF	Citations
19	lgG Effector Mechanisms. Chemical Immunology and Allergy, 1996, 65, 88-110.	1.7	42
20	Developing recombinant HPA-1a–specific antibodies with abrogated Fcγ receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. Journal of Clinical Investigation, 2008, 118, 2929-38.	8.2	42
21	Cell-surface markers on haemopoietic precursors. Reagents for the isolation and analysis of progenitor cell subpopulations. Molecular and Cellular Probes, 1987, 1, 297-326.	2.1	40
22	The influence of the hinge region length in binding of human IgG to human $Fc\hat{l}^3$ receptors. Human Immunology, 1998, 59, 720-727.	2.4	40
23	A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti-HPA-1a. British Journal of Haematology, 2000, 108, 440-447.	2.5	40
24	THERAPEUTIC POTENTIAL OF MONOCLONAL ANTIBODIES TO THE LEUKOCYTE-COMMON ANTIGEN. Transplantation, 1985, 40, 538-544.	1.0	39
25	Human IgG isotypes and activating $Fc\hat{l}^3$ receptors in the interaction of <i>Salmonella enterica</i> serovar Typhimurium with phagocytic cells. Immunology, 2011, 133, 74-83.	4.4	38
26	Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology, 1998, 93, 595-600.	4.4	34
27	Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. Blood, 2013, 122, 313-320.	1.4	34
28	The use of phage-peptide libraries to define the epitope specificity of a mouse monoclonal anti-Der p 1 antibody representative of a major component of the human immunoglobulin E anti-Der p 1 response. Clinical and Experimental Allergy, 1999, 29, 1563-1571.	2.9	32
29	Immunohistological screening in the selection of monoclonal antibodies: the use of isotype-specific antiglobulins. Journal of Immunological Methods, 1984, 69, 207-214.	1.4	30
30	Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood, 2006, 107, 2619-2626.	1.4	30
31	Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduction and Targeted Therapy, 2016, 1 , .	17.1	30
32	The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochemical Society Transactions, 2002, 30, 495-500.	3.4	28
33	Function-blocking antibodies to human vascular adhesion protein-1: A potential anti-inflammatory therapy. European Journal of Immunology, 2005, 35, 3119-3130.	2.9	28
34	Rapid phenotyping of HPA-1a using either diabody-based hemagglutination or recombinant IgG1-based assays. Transfusion, 1999, 39, 781-789.	1.6	24
35	Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunology, Immunotherapy, 1994, 39, 391-396.	4.2	23
36	The effect of recombinant IgG antibodies against the leucine-33 form of the platelet \hat{l}^2 3 integrin (HPA-1a) on platelet function. Thrombosis and Haemostasis, 2004, 91, 743-754.	3.4	21

3

#	Article	IF	Citations
37	PECAM-1 Polymorphism Affects Monocyte Adhesion to Endothelial Cells. Transplantation, 2008, 85, 471-477.	1.0	21
38	Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge. Scientific Reports, 2019, 9, 7363.	3.3	21
39	BLOCKING OF CYTOTOXIC T CELL FUNCTION BY MONOCLONAL ANTIBODIES AGAINST THE CD45 ANTIGEN		

#	Article	IF	CITATIONS
55	Empowering the inventor—the case of monoclonal antibodies. Nature Biotechnology, 2005, 23, 1047-1049.	17.5	3
56	A Chimeric Antibody to Varicella-Zoster Virus Glycoprotein E. Hybridoma, 2005, 24, 50-54.	0.4	3
57	Lowâ€affinity FcγR interactions can decide the fate of novel human IgGâ€sensitised red blood cells and platelets. European Journal of Immunology, 2014, 44, 905-914.	2.9	3
58	Recombinant human IgG molecules lacking $Fc\hat{l}^3$ receptor I binding and monocyte triggering activities. , 1999, 29, 2613.		3
59	Chimeric and humanised—misunderstood. Lancet, The, 2000, 355, 1557.	13.7	2
60	Regulation unmasked by activation. Nature Immunology, 2013, 14, 696-697.	14.5	2
61	Interaction of rat monoclonal antibodies with human killer cells (K cells). Biochemical Society Transactions, 1984, 12, 877-878.	3.4	1
62	Immunology Interactive 2.0 CD-ROM. Trends in Immunology, 1999, 20, 56.	7. 5	1
63	Clearance of Human IgG1-Sensitised Red Blood Cells In Vivo in Humans Relates to the In Vitro Properties of Antibodies from Alternative Cell Lines. PLoS ONE, 2014, 9, e109463.	2.5	1
64	Principles of cellular and molecular immunology. Trends in Cell Biology, 1994, 4, 70.	7.9	0
65	One IgG receptor, two different functions. Lancet, The, 1996, 347, 1104.	13.7	0
66	Two different roles for the neonatal IgG Fc receptor FcRn?. Trends in Immunology, 1996, 17, 251.	7. 5	0
67	Recombinant antibodies, by Frank Breitling and Stefan Dübel. Trends in Immunology, 2000, 21, 412.	7.5	0
68	Immunochemical applications., 0,, 627-656.		0
69	Development and Clinical Experience with Humanised Monoclonal Antibodies. Developments in Biotherapie, 1990, , 195-199.	0.1	O